VMD: financial statements from SEC — TradeAlmanac

VMD

Viemed Healthcare, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024
Revenue	270m	224m
Cost of revenue	115m	91m
Gross profit	155m	133m
Research and development	3m	3m
Selling, general and administrative	121m	106m
Operating income	23m	18m
Pre-tax income	22m	16m
Income tax	6m	5m
Net income	15m	11m
Earnings per share	0.38	0.29
Earnings per share, diluted	0.37	0.28
Weighted average shares	39m	39m
Weighted average shares, diluted	41m	41m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	10m	14m	11m	20m	10m	18m	11m	9m
Receivables	31m	26m	27m

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024
Operating cash flow	52m	39m
Depreciation and amortisation	29m	25m
Share-based compensation	9m	6m
Capital expenditure	40m	38m
Investing cash flow	−50m	−31m
Share buybacks	13m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)